Gaeta Renee 4

What Happened Renee Gaeta, a director of Candel Therapeutics, was granted an award to acquire 32,000 shares (derivative equity) on June 23, 2026. The filing reports an acquisition price of $0.00 (reported value $0) — this is a grant/award of derivative securities (options or similar), not a market purchase or sale.

Key Details

• Transaction date: 2026-06-23; filing date (Form 4): 2026-06-24 (timely).
• Transaction type/code: Grant/Award (A); derivative security reported.
• Quantity: 32,000 underlying shares; reported acquisition price: $0.00; total reported value: $0.
• Shares owned after transaction: Not specified in the information provided in this summary.
• Footnote: The award is subject to time‑based vesting — vests on the earlier of (i) June 23, 2027 or (ii) the next Annual Meeting of Stockholders; vesting ceases if the reporting person resigns or stops serving as a director unless the Board decides otherwise.

Context This was an equity compensation award for a board member, not an exercise or sale. Awards like this are common as director compensation and do not by themselves indicate immediate buying or selling of stock; the awarded options must vest per the terms before they can be exercised or sold.